

## Hemovigilance Module Adverse Reaction Delayed Hemolytic Transfusion Reaction

*Required for saving	
*Facility ID#: NHSN A	dverse Reaction #:
Patient Information	
*Patient ID:	*Gender: M F Other *Date of Birth:
Social Security #:	Secondary ID:            Medicare #:
Last Name:	First Name: Middle Name:
Ethnicity Hispanic or Latino	Not Hispanic or Not Latino
Race American Indian/Alas  Native Hawaiian/Oth	
*Blood Group: A- A+ Transitional ABO /	B- B+ AB- AB+ O- O+ Blood type not done Transitional ABO / Rh - Rh
Group A/Transitional Grou	p B/Transitional Group O/Transitional Rh Group AB/Transitional Rh
Patient Medical History	
List the patient's admitting diagno	sis. (Use ICD-10 Diagnostic codes/descriptions)
Code:	Description:
Code:	Description:
Code:	Description:
List the patient's underlying indica	ation for transfusion. (Use ICD-10 Diagnostic codes/descriptions)
Code:	Description:
Code:	Description:
Code:	Description:
	ons at the time of the transfusion related to the adverse UNKNOWN codes/descriptions)
Code:	Description:
Code:	Description:
Code:	Description:



Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333 ATTN: PRA (0920-0666).



		ical procedure including pas nospital or outpatient stay. (			s to be UNKNOWN  NONE
Code:	_	Description:			
Code:					<del></del>
Code:	_	Description:			
Additional Information					
Transfusion History					
Has the patient received a	pre	vious transfusion?	YE	S NO	UNKNOWN
Blood Product:	W	'B RBC Platelet	Plasma	a Cryoprec	ipitate Granulocyte
Date of Transfusion:	-	/ UNK	KNOWN		
Was the patient's adverse	e re	action transfusion-related?		YES	NO
If yes, provide information	n al	oout the transfusion adverse	e reaction.		
Type of transfusion adver	rse	reaction: Allergic	AHTR	DHTR	DSTR FNHTR
HTR TTI		PTP TACO TAI	D TA-G	GVHD TRA	ALI UNKNOWN
OTHER Specif	ify _				
Reaction Details					
*Date reaction occurred:	/	/ *Time reaction o	occurred: _	:	Time unknown
*Facility location where patie	ient	was transfused:			
Is this reaction associated with	h ar	n incident? Yes	No	If Yes, Inciden	t #:
Investigation Results (Or	nly a	answer questions listed und	ler the selec	ted reaction type	.)
* Delayed hemolytic trans	sfu	sion reaction (DHTR)			
Immune Antibody:		Non-	immune (sp	ecify)	
*Case Definition					
	occ	urred <b>between 24 hours a</b> i	nd 28 davs	after cessation o	f transfusion:
Positive direct antigle					
		od cell alloantibody in recipi	ent serum		
		alloantibody present on the		red blood cells	
		ansfusion hemoglobin level o			to pre-transfusion levels
		appearance of spherocytes	•	3	, , , , , , , , , , , , , , , , , , ,
Check all that apply:		арроси си ор погод со			
Incomplete laborator	Λ. Δ'	vidence			
	•	reported symptoms, test re	sculte and/or	r available inform	eation are not sufficient
Diffix is suspected,	but	reported symptoms, test re	Suits, and/or	i avallable illioitti	ation are not sumcient
Other signs and symptoms: (c	chec	ck all that apply)			
Generalized:		Chills/rigors	Fever		Nausea/vomiting
Cardiovascular:		Blood pressure decrease		Shock	
Cutaneous:		Edema	Flushing		Jaundice
Hemolysis/Hemorrhage:	-	Other rash Disseminated intravascula	Pruritus (it		Urticaria (hives) Hemoglobinemia
HEIHOIVSIS/HEIHOITHAUC.	1 1	T DISSETTIFIALEU ITILIAVASCUIA	ıı coauulali0	11	i i ici i oulouli ici i id



Pain:	Abdominal pain	ı 🔲 B	ack pain	Flank pain		Infusion site pain
Renal:	Hematuria		Hemoglo	binuria	0	liguria
Respiratory:	Bilateral infiltrat	es on che	est x-ray	Bronchospas	m	Cough
respiratory.	Hypoxemia		Shortnes	s of breath		
Other: (specify)						
*Severity			_			
Did the patient receive or e			ŭ			
No treatment requ	ired		Symptomatic	treatment only		
Hospitalization, inl	cuding prolonged ho	ospitaliza	tion	Life-threat	tenir	ng reaction
Disability and/or in	capacitation		Congenital ar	nomaly or birth def	fect(	s) of the fetus
Other medically im	portant conditions		Death	Unknown	or n	ot stated
*Imputability						
Which best describes the r	elationship between	the trans	fusion and th	ne reaction?		
No other explanation	for symptoms or ne	ewly-ident	ified antibody	y is present.		
An alternate explana likely cause.	tion for symptoms o	r newly-io	lentified antib	oody is present, bu	ut tra	ansfusion is the most
Other explanations for ruled out.	or symptoms or new	ıly-identifi	ed antibody a	are more likely, bu	t tra	nsfusion cannot be
Evidence is clearly in	favor of a cause of	her than t	the transfusio	n hut transfusion	car	anot he excluded
There is conclusive 6						
	-					
The relationship betv	veen the adverse rea	action an	u the transiu	sion is unknown o	r no	i stated.
Did the transfusion occur a	t your facility?	YES	NO			
Did the translation occar a	t your raomey.	0				
<b>Module-generated Desig</b>	nations					
NOTE: Designations for case		and imput	ability will be	automatically ass	igne	ed in the NHSN
application based on response	es in the correspond	ling inves	tigation resul	ts section above.		
			_	□ v=0		
*Do you agree with the		signation	?	YES		∐ NO
^Please indicate your des	signation					
*Do you agree with the	severity designation	n?		YES		NO
^Please indicate your des						
	<u></u>					
*Do you agree with the	i <u>mputability</u> design	nation?		YES		NO
^Please indicate your des	signation					<del></del>
Patient Treatment						
Did the patient receive treat	ment for the transfu	sion reac	tion?	YES I	ИO	UNKNOWN
If yes, select treatment(s):						
Medication (Select	the type of medication	on)				
Antipyretics		•	s/Vasopresso			
Intravenous			us steroids	Corticostero	ids	Antibiotics
CDC 57.309 Rev.2, v9.2	F	Page 4 of 6				



In	nmunoglobulin				·······ouo.go	***************************************
Antithymocyte globulin Cyclosporin Other						
Volume resuscitation (Intravenous colloids or crystalloids)						
Res	piratory support <i>(Sele</i>	ect the type of s	upport)			
	Mechanical ventilat	ion Noni	nvasive ventilation	Oxygen		
Rer	al replacement therap	oy <i>(Select the t</i> y Peritoneal		no-Venous Hem	ofiltration	
Phle Oth	ebotomy er Specify:					
Outcome						
*Outcome: Date of		lajor or long-teri		Minor or no equelae	Not deter	mined
	Definite Probabl			Ruled Ou	t Not determin	ed
Cause	of death:					
Was an	autopsy performed?	Yes	No			
Component						
*Was a partion?	cular unit implicate	d in (i.e., resp	onsible for) the a	idverse	Yes No	N/A
Transfusion Start and End Date/Time	*Component code (check system used)	Amount transfused at reaction onset	^Unit number (Required for Infection and TRALI)	*Unit expiration Date/Time	*Blood group	Implic ated Unit?
^IMPLICATED						
	ISBT-128 Codabar	Entire unit Partial unitmL			A- A+ B- B+ AB- AB+ O- O+ N/A	Y
	ISBT-128 Codabar 	Entire unit Partial unitmL		::	A- A+ B- B+ AB- AB+ O- O+ N/A	- N
Custom Fields						
Label			Label			
		1				
Comments						



CDC 57.309 Rev.2, v9.2